文献速递妇科

子宫内膜癌初始化疗患者静脉血栓栓塞发生率高达26.7%

High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention.
PubMed 文献 · Gynecol Oncol · 2026-08-29

癌症分期与VTE发生相关(p < 0.001),发生VTE者中50.0%为IV期,而未发生VTE者中IV期占20.4%。讨论指出需改进风险评估工具并评估预防性抗凝。

要点

  • 接受初始化疗的子宫内膜癌患者中超过1/4发生VTE。
  • 癌症分期是唯一与后续VTE相关的因素,IV期患者占比更高。
  • 组织学类型、分级、BMI及Khorana评分与VTE发生无关。

核心结论

  • 接受初始化疗的子宫内膜癌患者VTE发生率超过1/4,癌症分期是唯一相关因素。

主要发现

  • 癌症分期与VTE发生相关(p < 0.001);发生VTE者中50.0%为IV期,未发生VTE者中IV期占20.4%。
  • 初始化疗开始时高风险Khorana评分(≥3)、组织学类型、分级、年龄、ECOG功能状态、吸烟、BMI及初始治疗期间接受盆腔外照射放疗、免疫治疗或贝伐珠单抗均与VTE发生无关。

临床怎么用

  • 对接受初始化疗的子宫内膜癌患者应提高VTE风险意识,尤其IV期患者。

局限性

  • 单中心回顾性设计,仅采用描述性统计,未报告多因素分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aim to describe the venous thromboembolism (VTE) rate among patients who received chemotherapy for initial endometrial cancer treatment, and identify factors associated with VTE diagnosis in this population. METHODS: This is a retrospective cohort study of patients who received chemotherapy during initial treatment for endometrial cancer from January 2015 to December 2023 within a single academic medical system. The primary outcome is overall VTE incidence. Sociodemographic and biomedical factors were collected. Descriptive statistics were used for analysis. RESULTS: Two hundred ninety-two patients were identified who received chemotherapy during initial treatment for endometrial cancer; 78 (26.7%) developed a VTE after cancer diagnosis. Cancer stage was associated with VTE development (p < 0.001); 50.0% of patients who developed VTE had Stage IV at diagnosis compared to 20.4% of those who did not. Twenty-four patients (30.8%) had carcinomatosis at the time of VTE diagnosis and 14 (17.9%) had ascites. A high-risk Khorana score (≥3) at initiation of initial chemotherapy, histology, grade, age, ECOG functional status, tobacco use, body mass index, and receipt of external beam pelvic radiation, immunotherapy, or bevacizumab during initial treatment were not associated with VTE development. DISCUSSION: More than 1 in 4 patients who received chemotherapy for initial endometrial cancer developed a VTE during their treatment course. Stage at cancer diagnosis was the only factor associated with subsequent VTE; factors including histology, grade, BMI and Khorana score were not associated. As endometrial cancer incidence rises, continued efforts to improve the accuracy of risk assessment tools and evaluate prophylactic anticoagulation in this high-risk population are warranted.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Thayer EG, Roecker ZA, Roof KA, et al. High rates of venous thromboembolism in endometrial cancer patients requiring systemic therapy: an opportunity for risk assessment and intervention. Gynecol Oncol. 2026. PMID: 42667794. doi:10.1016/j.ygyno.2026.08.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。